Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 25;6(4):e00207.
doi: 10.1097/BS9.0000000000000207. eCollection 2024 Oct.

Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation

Dao-Xing Deng  1 , Xiao-Hang Ma  1 , Ze-Hua Wu  1   2 , Xiao-Hui Zhang  1 , Lan-Ping Xu  1 , Yu Wang  1 , Chen-Hua Yan  1 , Huan Chen  1 , Yu-Hong Chen  1 , Wei Han  1 , Feng-Rong Wang  1 , Jing-Zhi Wang  1 , Xiao-Jun Huang  1   3 , Xiao-Su Zhao  1   4 , Xiao-Dong Mo  1   4
Affiliations

Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation

Dao-Xing Deng et al. Blood Sci. .

Abstract

We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (KMT2A-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of KMT2A-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with KMT2A-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with KMT2A-PTD ≥1% before HSCT had a slower decrease of KMT2A-PTD after HID HSCT. Patients with KMT2A-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with KMT2A-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, P = .010). In multivariable analysis, KMT2A-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; P = .025). Thus, pre-transplantation levels of KMT2A-PTD could predict relapse in AML patients following HID HSCT.

Keywords: Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Haploidentical; KMT2A-PTD; Relapse.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.
KMT2A-PTD achieving negative at 1, 2, 3 mo and ultimately after HID HSCT. HID HSCT = haploidentical donor hematopoietic stem cell transplantation, KMT2A-PTD = lysine (K)-specific methyltransferase 2A partial tandem duplication.
Figure 2.
Figure 2.
The dynamic variation of KMT2A-PTD before and after HID HSCT. HID HSCT = haploidentical donor hematopoietic stem cell transplantation, KMT2A-PTD = lysine (K)-specific methyltransferase 2A partial tandem duplication.
Figure 3.
Figure 3.
Comparison of clinical outcomes between patients with KMT2A-PTD <0.1%, ≥0.1% but <1%, and ≥1% before HID HSCT. (A) Cumulative incidence of relapse, (B) non-relapse mortality, (C) leukemia-free survival, (D) overall survival. HID HSCT = haploidentical donor hematopoietic stem cell transplantation, KMT2A-PTD = lysine (K)-specific methyltransferase 2A partial tandem duplication.
Figure 4.
Figure 4.
Comparison of clinical outcomes between patients with KMT2A-PTD <1%, and ≥1% before HID HSCT. (A) Cumulative incidence of relapse, (B) non-relapse mortality, (D) leukemia-free survival, (D) overall survival. HID HSCT = haploidentical donor hematopoietic stem cell transplantation, KMT2A-PTD = lysine (K)-specific methyltransferase 2A partial tandem duplication.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lv M, Shen M, Mo X. Development of allogeneic hematopoietic stem cell transplantation in 2022: regenerating “Groot” to heal the world. Innovation (Camb) 2023;4(1):100373. - PMC - PubMed
    1. Lv M, Gorin NC, Huang XJ. A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade. Sci Bull (Beijing) 2022;67(19):1921–1924. - PubMed
    1. Wang L, Zhang C, Fan S, Mo X, Hu X. Treatment options for adult intermediate-risk AML patients in CR1: allo-HSCT or chemotherapy? Innovation (Camb) 2023;4(4):100461. - PMC - PubMed
    1. Cao Y, Zhang C, Cao L, Mo X, Hu X. Quizartinib is a good option for AML patients with FLT3-ITD mutations. Innov Med 2023;1(1):100007.
    1. Deng D, Shen M, Zhang X, et al. . Basiliximab is the potential solution for severe liver chronic GVHD: a prospective pilot study. Innov Med 2023;1(1):100009. doi:10.59717/j.xinn-med.2023.100009.

LinkOut - more resources